

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTEES :	Merck HDAC Research, LLC; Sloan-Kettering Institute for Cancer Research	CONFIRMATION NO. :	6445
SERIAL NUMBER :	10/650,025	EXAMINER :	P. G. Spivack
FILING DATE :	August 26, 2003	ART UNIT :	1614
PATENT NO. :	7,148,257 B2	ISSUE DATE :	December 12, 2006
FOR :	METHODS OF TREATING MESOTHELIOMA WITH SUBEROYLANILIDE HYDROXAMIC ACID		

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.323

The Patentees of the above-identified patent, through their attorney, hereby request issuance of a Certificate of Correction to amend the specification to disclose the parties to a joint research agreement.

Pursuant to 37 CFR § 1.71(g)(3), Patentees request that the following section be included at column 1, line 20 of US 7,148,257, after the paragraph entitled "Government Interest Statement" and before the paragraph entitled "Field of the Invention":

REFERENCE TO JOINT RESEARCH AGREEMENT

Certain subject matter claimed herein was made under a Joint Research Agreement between Aton Pharma, Inc. and Sloan-Kettering Institute for Cancer Research and its affiliate Memorial Hospital for Cancer and Allied Diseases.

The amendment is not believed to involve such change as would constitute new matter or require examination.

It is respectfully requested that a Certificate of Correction be issued pursuant to 37 CFR § 1.323. Enclosed herewith is a copy of a proposed Certificate of Correction.


Please send the issued Certificate of Correction to Customer No. **35437**:

Name: Ivor R. Elrifi, Ph.D., Esq.
Address: Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
One Financial Center
Boston, MA 02111

REMARKS

Payment of the fee set forth in 37 CFR §1.20(a) (\$100) is provided herein. The patentees believe the requirements for a certificate of correction have been met herein and respectfully request issuance of same. Should the Certificates Branch wish to discuss patentees' request, the Certificates Branch is invited to telephone the undersigned attorney at 617/542-6000. No additional fees are believed due in connection with this submission; however, the Commissioner is hereby authorized to charge any additional fees due, or credit any overpayment of same, to Deposit Account No. **50-0311**; Reference No. **24852-501004US**; Customer No. **35437**.

Respectfully submitted,


For: Ivor R. Elrifi, Reg. No. 39,529 52,972
Attorney for Applicant
c/o MINTZ LEVIN
One Financial Center
Boston, MA 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: June 10, 2011